New CAR-T therapy SYNCAR-100 enters early human testing for tough leukemia
NCT ID NCT07429461
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests SYNCAR-100, a type of cell therapy (CAR-T), in 16 adults with CD19-positive B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatment. Participants receive four weekly injections, then are followed for safety and tumor response for one year, with long-term monitoring up to 15 years. The main goal is to check safety and tolerability, with secondary goals looking at how well the therapy works against the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SYNCAR-100 (a CAR-T cell therapy)
What this could lead to
If it works, this could point toward a new treatment option for patients with hard-to-treat B-cell acute lymphoblastic leukemia.
What could go wrong
This is a very early, small study (16 people) focused on safety, not proof of effectiveness. The therapy may cause severe side effects or fail to control the disease long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The first affiliated hospital of medical college of zhejiang university
RECRUITINGHangzhou, Zhejiang, 310003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••